Meta-analyses of methylation markers for prostate cancer

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10449-10455

  Jiang, Danjie ^a   Shen, Yusheng ^a   Dai, Dongjun ^a   Xu, Yan ^a   Xu, Chunjing ^a   Zhu, Huangkai ^a   Huang, Tao ^a   Duan, Shiwei ^a  

^a NINGBO UNIVERSITY   (China)

Author keywords

DNAmethylation; Epigenetics; Prostate cancer

Indexed keywords

GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; RASSF1 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BETA; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADENOCARCINOMA; DNA METHYLATION; GENETICS; HUMAN; MALE; META ANALYSIS; PROSTATE TUMOR; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; DNA METHYLATION; GENES, P16; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84922394341     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2300-7     Document Type: Article

References (35)

1. Greenlee RT,Murray T, Bolden S,Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
2. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part i: International comparisons. BJU Int. 2002;90:162-73.
3. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121:1571-8.
4. Smith DS, Bullock AD, Catalona WJ, Herschman JD. Racial differences in a prostate cancer screening study. J Urol. 1996;156:1366-9.
5. Spence AR, Rousseau MC, Karakiewicz PI, Parent ME: Circumcision and prostate cancer: A population-based case-control study in montreal, canada. BJU international 2014.
6. Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF,WildhagenMF, Hop WC, et al. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am J Pathol. 2001;158:399-406.
7. Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostatecancer screening trial. N Engl J Med. 2009;360:1310-9.
8. Klotz L, Zhang L, Lam A, Nam R,Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126-31.
9. Tourville EA, NguyenMM. Prostate cancer detection by using digital rectal examination: contemporary practice patterns in the united states. Clin Genitourin Cancer. 2013;11:263-9.
10. Lorincz AT. Cancer diagnostic classifiers based on quantitative DNA methylation. Expert Rev Mol Diagn. 2014;14:293-305.
11. Heyn H, Sayols S,Moutinho C, Vidal E, Sanchez-Mut JV, Stefansson OA, et al. Linkage of DNA methylation quantitative trait loci to human cancer risk. Cell Rep. 2014;7:331-8.
12. Dong Y, Zhao H, Li H, Li X, Yang S. DNA methylation as an early diagnostic marker of cancer (review). Biomed Rep. 2014;2: 326-30.
13. Jiang D, Hong Q, Shen Y, Xu Y, Zhu H, Li Y, et al. The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis. PLoS ONE. 2014;9:e96822.
14. Chen C, Wang L, Liao Q, Huang Y, Ye H, Chen F, et al. Hypermethylation of ednrb promoter contributes to the risk of colorectal cancer. Diagn Pathol. 2014;8:199.
15. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant cpg island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol. 2004;202:233-40.
16. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer- Muller S, Farinas AJ, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res. 2002;8:514-9.
17. Chao C, Chi M, Preciado M, Black MH. Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control. 2014;24:1615-41.
18. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, et al. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst. 2006;98:255-61.
19. RoupretM, Hupertan V, Catto JW, Yates DR, Rehman I, Proctor LM, et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer. 2008;122:952-6.
20. Jeronimo C, Bastian PJ, Bjartell A, CarboneGM, Catto JW, Clark SJ, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol. 2011;60:753-66.
21. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W. The epigenetic promise for prostate cancer diagnosis. Prostate. 2012;72:1248-61.
22. DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med. 1996;15:1237-48. discussion 1249-1252.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ Clin Res Ed. 2003;327:557-60.
24. Bax L, Ikeda N, Fukui N, Yaju Y, Tsuruta H, Moons KG. More than numbers: the power of graphs in meta-analysis. Am J Epidemiol. 2009;169:249-55.
25. Tew KD, Manevich Y, Grek C, Xiong Y, Uys J, Townsend DM. The role of glutathione S-transferase P in signaling pathways and Sglutathionylation in cancer. Free Radic Biol Med. 2011;51:299-313.
26. Meiers I, Shanks JH, Bostwick DG. Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: Review 2007. Pathology. 2007;39:299-304.
27. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005;65:3497-508.
28. Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res. 2007;13:2541-8.
29. Shapiro GI, Rollins BJ. P16ink4a as a human tumor suppressor. Biochim Biophys Acta. 1996;1242:165-9.
30. Mori T,Miura K, Aoki T, Nishihira T,Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/ cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 1994;54:3396-7.
31. Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M, Nakamura Y. Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun. 1994;202:1426-30.
32. Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood. 1995;86:1269-75.
33. Ines FM, Gauna GV, Lis SM, Beatriz NS, Matias SA, Maria VR: Retinoic acid reduces migration of human breast cancer cells: role of retinoic acid receptor beta. J Cell Mol Med 2014.
34. Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, et al. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res. 2004;10: 4010-4.
35. Zhang W, Ma Z, Lu S, Wang R, Zhao P, Wang L. Correlation of dnmt1 expression with gstp1 and apc methylation and its clinical significance. Acta Academiae Medicinae Militaris Tertiae 2011;33(15):4602-5.